A 32-year-old woman with a history of bipolar I disorder comes to the outpatient psychiatr… — USMLE Step 2 CK

A 32-year-old woman with a history of bipolar I disorder comes to the outpatient psychiatry clinic due to a 4-week history of depressed mood, profound fatigue, and sleeping up to 14 hours a day. Her last manic episode occurred two years ago, and she has been maintained on a stable dose of valproate since that time. Vital signs include a heart rate of 72/min, blood pressure of 118/76 mm Hg, and respiratory rate of 14/min. Mental status examination reveals psychomotor retardation, a blunted affect, and a sad mood. She denies any suicidal ideation. The physician decides to add lamotrigine to her current regimen to target the depressive symptoms. To minimize the risk of a life-threatening dermatologic complication, which of the following pharmacokinetic principles must be applied to the management of this patient?

Valproate inhibits the glucuronidation of lamotrigine, requiring a lower starting dose of lamotrigine.Answer
B
Valproate induces the cytochrome P450 metabolism of lamotrigine, requiring a higher starting dose of lamotrigine.
C
Lamotrigine displaces valproate from plasma binding proteins, requiring a reduction in the valproate dose.
D
Lamotrigine accelerates the hepatic metabolism of valproate, requiring an increase in the valproate dose.
E
Both medications compete for renal tubular secretion, requiring strict alternate-day dosing schedules.

Answer

Valproate inhibits the glucuronidation of lamotrigine, requiring a lower starting dose of lamotrigine.

The correct principle is that valproate inhibits the hepatic glucuronidation of lamotrigine. Lamotrigine is primarily metabolized in the liver by uridine 5'-diphospho-glucuronosyltransferase (UGT). Valproate is a strong inhibitor of UGT. When lamotrigine is added to a regimen containing valproate, its clearance is significantly decreased, and its elimination half-life is nearly doubled. Because rapid escalation of lamotrigine serum levels is the most significant risk factor for developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), the starting dose of lamotrigine must be reduced (usually by 50%, e.g., to 25 mg every other day) and titrated much more slowly in patients taking valproate.

Step-by-Step Solution

Identify the primary clinical objective and the current medication regimen.

The goal is to initiate lamotrigine for breakthrough bipolar depression in a patient currently taking valproate.

Establishing the medication combination is essential for identifying potential drug-drug interactions.

Recall the metabolic pathways and interaction profiles of the specific psychotropic agents.

Valproate is a broad inhibitor of hepatic enzymes, most notably uridine 5'-diphospho-glucuronosyltransferase (UGT), which is the exact enzyme responsible for clearing lamotrigine.

Understanding the pharmacokinetics dictates how the new medication should be prescribed.

Determine the clinical consequence of the interaction.

Inhibition of UGT by valproate nearly doubles the elimination half-life of lamotrigine. Rapid escalation of lamotrigine levels is the primary risk factor for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

The question specifically asks how to avoid a life-threatening dermatologic complication (SJS).

Select the appropriate clinical management principle.

The starting dose and titration schedule of lamotrigine must be significantly reduced (typically by 50%) when added to valproate.

This directly answers the prompt's question regarding the necessary pharmacokinetic adjustments.

Key Concept

Valproate inhibits hepatic glucuronidation (UGT), doubling the half-life of lamotrigine. To prevent Stevens-Johnson syndrome, lamotrigine must be initiated at a reduced dose when prescribed with valproate.

Estimated Time:1m 15s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic